Search results

This one is quite frustratingly vague and doesn't seem to add much to their previous findings. There are two parts: Data from their registry of 845 patients with Long Covid. This shows common symptoms, but nothing new that we haven't seen before in much larger studies. Then they discuss linking...

Abstract Background Fibrin(ogen) amyloid microclots and platelet hyperactivation previously reported as a novel finding in South African patients with the coronavirus 2019 disease (COVID-19) and Long COVID/Post-Acute Sequelae of COVID-19 (PASC), might form a suitable set of foci for the clinical...

This seems very high! Were there any details about when this research will be published?

In round numbers, I think the latest data shows about 50% protection against infection from a recent booster. Protection against Long Covid is harder to quantify, but probably around 50% according to ONS data. Some studies have shown a lot lower protection against LC (particularly the Al-Aly VA...

Abstract A proportion of COVID-19 reconvalescent patients develop post-COVID-19 syndrome (PCS) including a subgroup fulfilling diagnostic criteria of Myalgic encephalomyelitis/Chronic Fatigue Syndrome (PCS/CFS). Recently, endothelial dysfunction (ED) has been demonstrated in these patients, but...

Preprint and final publication threads merged Final publication abstract further down the thread here Abstract Background: Post COVID-19 condition (PCC) is defined as symptoms lasting more than 12 weeks after developing COVID-19. Evidence of mitochondrial dysfunction has been reported in...

Here's the study.

This study has a quite striking chart showing how requiring pre-registration of primary outcomes appears to have significantly reduced the likelihood of positive trial findings in this area: Abstract Background We explore whether the number of null results in large National Heart Lung, and...

They appear to be separating LC into three clusters: neurological (anosmia/dysosmia, fatigue, brain-fog, depression, delirium and headache), cardiorespiratory and systemic/inflammatory /abdominal symptoms /myalgias (rashes, pain, gut problems, dizziness, fever, hair loss, etc). It's not really...

Abstract Background: Self-reported symptom studies rapidly increased our understanding of SARS-CoV-2 during the pandemic and enabled the monitoring of long-term effects of COVID-19 outside the hospital setting. It is now evident that post-COVID syndrome presents with heterogeneous profiles...

I think I've only seen BA.1 vaccines (planned for Europe, probably Canada) and BA.4/5 vaccines (USA). but BA.2 would probably make more sense because BA.2.75, which as the code indicates is a descendant of BA.2, could potentially be the next variant. It's showing faster growth than BA.5 in India...

I got Novavax for my fourth shot a few days ago and found the side effects were minimal (slightly sore arm, maybe a little bit worsened general ME symptoms but that could have just been normal variability). In comparison, all three of my previous Moderna shots resulted in significant flu-like...

Lately, they seem to be trying to push Ampligen as an antiviral against Covid (as a nasal spray prophylactically and as a treatment). Plus a bunch of different cancers, in flu vaccines and HIV. It doesn't really inspire confidence.

Slides from Dr. Roy's presentation today at IACFS/ME about their work on a mouse model for ME with a drug that acts on mTOR -> ATG13 -> autophagy impairment. It definitely does something that looks a bit like PEM, if I'm understanding the slides correctly, and much more effectively in female...

Post copied from Elevated ATG13 in serum of pwME stimulates oxidative stress response in microglial cells , 2022, Gottschalk et al Slides from Dr. Roy's presentation today at IACFS/ME about their work on a mouse model for ME with a drug that acts on mTOR -> ATG13 -> autophagy impairment. It...

Always suspicious when they don't give confidence intervals in the abstract. Some of these are significant at 0.05, some are not, but they don't adjust for multiple comparisons. If they did, I doubt more than a couple of these associations would be significant (maybe EBV early antigen-D and...

What jumped out at me is that women were half as likely to recover their sense of smell as men and one third as likely to recover their sense of taste as men in this meta-analysis. Perhaps this points to a shared underlying mechanism between ME-type Long Covid and loss of sense or smell or taste.

Abstract Objective To clarify in patients with covid-19 the recovery rate of smell and taste, proportion with persistent dysfunction of smell and taste, and prognostic factors associated with recovery of smell and taste. Design Systematic review and meta-analysis. Data sources PubMed, Embase...

I'm surprised that IBS is no more common in ME in this survey than in the general population. Or perhaps ME patients have gut issues, but don't call them IBS.

I think part of the problem is that you have a group of people who insist that LC risk is 20-50% per infection and possibly higher for re-infections (thanks to that poorly done Al-Aly VA study), so they conclude that everyone or most will have LC within a couple years. And then there's another...